Cette recherche s'applique uniquement aux ressources en bibliothèque.
142 résultats
Trier par:
Ajouter à la liste:
    • Plusieurs versions

    Berkeley Supernova Ia Program – IV. Carbon detection in early-time optical spectra of Type Ia supernovae

    Silverman, Jeffrey M, Filippenko, Alexei V
    Monthly Notices of the Royal Astronomical Society, 2012, Vol. 425(3), pp.1917-1933 [Revue évaluée par les pairs]

    • Film
    Sélectionner

    Sparrows

    Beaudine, William, 1892-1970, Sullivan, Crawford Gardner, 1884-1965, Silverman, Jeffrey
    [Blagnac] : Les Films du Paradoxe
    2010
    Recherche de la disponibilité
    Plus…
    Chargement
    Erreur de chargement
    Titre: Sparrows / un film de William Beaudine ; scénariste C. Gardner Sullivan ; musique Jeffrey Silverman
    Auteur: Beaudine, William, 1892-1970; Sullivan, Crawford Gardner, 1884-1965; Silverman, Jeffrey
    Editeur: [Blagnac] : Les Films du Paradoxe
    Date: 2010
    Collation: 1 DVD-vidéo (90 min.) : noir et blanc teinté
    Collection: [Stars du muet d'Hollywood]
    Milestone restauration
    Documents dans cette collection: [Stars du muet d'Hollywood] - Milestone restauration
    Contient: Bonus: Présentation du film (12') ; "Ramona" court métrage de D.W. Griffith (1910, n/b, 17')
    Description: Drame
    Interprètes: Mary Pickford ; Roy Stewart ; Mary Louise Miller ; Gustav von Seyffertitz ; Charlotte Mineau ; "Spec" O'Donnell ... et al.
    Note: Une prod.: Pickford Corp., cop. 1926 - Film muet avec dialogues sous-titrés en français
    Note: Image Charles Rosher, Karl Struss et Hal Mohr
    Classification: vs-pratdvd SPAR
    Identifiant: 3760010555965 (ISBN)
    No RERO: R005928706
    Permalien:
    http://data.rero.ch/01-R005928706/html?view=VS_V1

    • Plusieurs versions

    Marqibo ® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine

    Silverman, Jeffrey, Deitcher, Steven
    Cancer Chemotherapy and Pharmacology, 2013, Vol.71(3), pp.555-564 [Revue évaluée par les pairs]

    • Plusieurs versions

    Berkeley Supernova Ia Program – V. Late-time spectra of Type Ia Supernovae

    Silverman, Jeffrey M, Ganeshalingam, Mohan, Filippenko, Alexei V
    Monthly Notices of the Royal Astronomical Society, 2013, Vol. 430(2), pp.1030-1041 [Revue évaluée par les pairs]

    • Plusieurs versions

    Berkeley Supernova Ia Program – II. Initial analysis of spectra obtained near maximum brightness

    Silverman, Jeffrey M, Kong, Jason J, Filippenko, Alexei V
    Monthly Notices of the Royal Astronomical Society, 2012, Vol. 425(3), pp.1819-1888 [Revue évaluée par les pairs]

    • Article
    Sélectionner

    Luminous blue variable eruptions and related transients: diversity of progenitors and outburst properties

    Smith, Nathan, Li, Weidong, Silverman, Jeffrey M, Ganeshalingam, Mohan, Filippenko, Alexei V
    Monthly Notices of the Royal Astronomical Society, 2011, Vol. 415(1), pp.773-810 [Revue évaluée par les pairs]
    Oxford University Press
    Disponible
    Plus…
    Titre: Luminous blue variable eruptions and related transients: diversity of progenitors and outburst properties
    Auteur: Smith, Nathan; Li, Weidong; Silverman, Jeffrey M; Ganeshalingam, Mohan; Filippenko, Alexei V
    Sujet: Instabilities ; Stars: Evolution ; Stars: Massive ; Stars: Mass - Loss ; Supernovae: General ; Stars: Winds, Outflows
    Description: We present new light curves and optical spectra for a number of extragalactic optical transients or ‘supernova impostors’ related to giant eruptions of luminous blue variables (LBVs), and we provide a comparative discussion of LBV-like giant eruptions known thus far. New data include photometry and spectroscopy of supernovae (SNe) 1999bw, 2000ch, 2001ac, 2002bu, 2006bv and 2010dn. SN 2010dn appears to be a carbon copy of SN 2008S and NGC 300-OT, whereas SN 2002bu shows spectral evolution from a normal LBV at early times to a twin of these cooler transients at late times. SN 2008S, NGC 300-OT and SN 2010dn appear to be special cases of a broader eruptive phenomenon where the progenitor star was enshrouded by dust, perhaps from a previous unseen eruptive episode. Evidence suggests that their progenitors have initial masses in the range 10–20 M ⊙ , extending the range of masses susceptible to the violent eruptive phenomenon below the canonical LBV mass range. Examining the full sample, SN impostors are characterized by strong photometric variability on a range of time-scales from a day to decades, potentially suffering multiple eruptions of the same source. The upper end of the luminosity distribution overlaps with the least-luminous core-collapse SNe, but in most cases a distinction can be made based on spectra. The low end of the luminosity distribution is far less well defined, and a distinction between LBV giant eruptions, S Doradus phases of LBVs, novae and possible eruptions of intermediate-mass stars is not entirely clear. We discuss observational clues concerning stellar winds or shocks as the relevant mass-loss mechanism, and we evaluate possible ideas for the physical mechanisms of outbursts, but there is still a great need for theoretical work on this problem . Although known examples of these eruptions are sufficient to illustrate their remarkably wide diversity in the peak absolute magnitude, duration, progenitor stars, outburst spectra and other observable properties, their statistical distribution is an area that will benefit greatly from current and upcoming transient surveys. Based on the distribution of these eruptive properties, we propose that the prototypical object SN 1961V was not a member of this class of impostors after all, but was instead a true core-collapse Type IIn SN that was preceded by a giant LBV eruption.
    Fait partie de: Monthly Notices of the Royal Astronomical Society, 2011, Vol. 415(1), pp.773-810
    Identifiant: 0035-8711 (ISSN); 1365-2966 (E-ISSN); 10.1111/j.1365-2966.2011.18763.x (DOI)

    • Plusieurs versions

    Berkeley Supernova Ia Program – III. Spectra near maximum brightness improve the accuracy of derived distances to Type Ia supernovae

    Silverman, Jeffrey M, Ganeshalingam, Mohan, Li, Weidong, Filippenko, Alexei V
    Monthly Notices of the Royal Astronomical Society, 2012, Vol. 425(3), pp.1889-1916 [Revue évaluée par les pairs]

    • Article
    Sélectionner

    Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

    Shah, Manish A, Starodub, Alexander, Sharma, Sunil, Berlin, Jordan, Patel, Manish, Wainberg, Zev A, Chaves, Jorge, Gordon, Michael, Windsor, Kevin, Brachmann, Carrie Baker, Huang, Xi, Vosganian, Greg, Maltzman, Julia D, Smith, Victoria, Silverman, Jeffrey A, Lenz, Heinz-Josef, Bendell, Johanna C
    Clinical cancer research : an official journal of the American Association for Cancer Research, 15 August 2018, Vol.24(16), pp.3829-3837 [Revue évaluée par les pairs]
    MEDLINE/PubMed (U.S. National Library of Medicine)
    Disponible
    Plus…
    Titre: Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
    Auteur: Shah, Manish A; Starodub, Alexander; Sharma, Sunil; Berlin, Jordan; Patel, Manish; Wainberg, Zev A; Chaves, Jorge; Gordon, Michael; Windsor, Kevin; Brachmann, Carrie Baker; Huang, Xi; Vosganian, Greg; Maltzman, Julia D; Smith, Victoria; Silverman, Jeffrey A; Lenz, Heinz-Josef; Bendell, Johanna C
    Sujet: Adenocarcinoma -- Drug Therapy ; Antibodies, Monoclonal -- Administration & Dosage ; Esophageal Neoplasms -- Drug Therapy ; Matrix Metalloproteinase 9 -- Genetics ; Stomach Neoplasms -- Drug Therapy
    Description: Matrix metalloproteinase-9 (MMP9) is implicated in protumorigenic processes. Andecaliximab (GS-5745, a monoclonal antibody targeting MMP9) was evaluated as monotherapy and in combination with mFOLFOX6. Three dosages of andecaliximab monotherapy [200, 600, and 1800 mg i.v. every 2 weeks (q2w)] were investigated in patients with advanced solid tumors ( = 13 in a 3+3 design). After determining a recommended dose, patients with advanced HER2-negative gastric/gastroesophageal junction (GEJ) adenocarcinoma ( = 40) received 800 mg andecaliximab + mFOLFOX6 q2w. Pharmacokinetics, pharmacodynamics, safety, and efficacy were assessed. Andecaliximab monotherapy demonstrated no dose-limiting toxicity (DLT) in any cohort, displaying target-mediated drug disposition at the lowest dose (200 mg) and linear pharmacokinetics at higher doses. Based on target engagement, recommended doses for further study are 800 mg q2w or 1,200 mg q3w. Maximal andecaliximab target binding, defined as undetectable andecaliximab-free...
    Fait partie de: Clinical cancer research : an official journal of the American Association for Cancer Research, 15 August 2018, Vol.24(16), pp.3829-3837
    Identifiant: 1078-0432 (ISSN); 29691300 Version (PMID); 10.1158/1078-0432.CCR-17-2469 (DOI)

    • Article
    Sélectionner

    Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules

    Advani, Ranjana H, Hurwitz, Herbert I, Gordon, Michael S, Ebbinghaus, Scot W, Mendelson, David S, Wakelee, Heather A, Hoch, Ute, Silverman, Jeffrey A, Havrilla, Nancy A, Berman, Craig J, Fox, Judith A, Allen, Roberta S, Adelman, Daniel C
    Clinical cancer research : an official journal of the American Association for Cancer Research, 01 April 2010, Vol.16(7), pp.2167-75 [Revue évaluée par les pairs]
    MEDLINE/PubMed (U.S. National Library of Medicine)
    Disponible
    Plus…
    Titre: Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules
    Auteur: Advani, Ranjana H; Hurwitz, Herbert I; Gordon, Michael S; Ebbinghaus, Scot W; Mendelson, David S; Wakelee, Heather A; Hoch, Ute; Silverman, Jeffrey A; Havrilla, Nancy A; Berman, Craig J; Fox, Judith A; Allen, Roberta S; Adelman, Daniel C
    Sujet: Drug Resistance, Neoplasm -- Drug Effects ; Naphthyridines -- Administration & Dosage ; Neoplasms -- Drug Therapy ; Thiazoles -- Administration & Dosage
    Description: Voreloxin, a novel replication-dependent DNA-damaging agent, intercalates DNA and inhibits topoisomerase II. Voreloxin induces site-selective DNA double-strand breaks and apoptosis. We report the phase 1 experience of voreloxin in patients with relapsed/refractory solid tumors, including dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics, and clinical activity. Two dose-escalation studies evaluated voreloxin administered i.v. every 3 weeks (SPO-0001) or weekly for 3 weeks every 28 days (SPO-0002). In SPO-0001, patients were classified as heavily pretreated (HP) or minimally pretreated (MP) based on therapeutic history. In the SPO-0001 study, 41 patients (24 HP/17 MP) were treated in eight dose cohorts (3-75 mg/m(2)). At 60 mg/m(2), four HP patients experienced DLTs: grade 4 neutropenia (n = 3, one with fever) and grade 3 febrile neutropenia/pneumonia (n = 1). At 75 mg/m(2), two MP patients experienced DLTs: grade 4 neutropenia/thrombocytopenia (n = 1) or grade 2 oral thrush for >29 days (n = 1). Therefore, the MTD was 48 mg/m(2) (HP patients) and 60 mg/m(2) (MP patients). In the SPO-0002 study, 21 patients were treated in six dose cohorts (3-24 mg/m(2)). At 18 mg/m(2), two patients experienced DLTs: grade 3 neutropenia, one with pleural effusion (>14 days each). The MTD was 15 mg/m(2). Voreloxin exhibited low clearance (2 L/h/m(2)), a long terminal half-life (22 hours), and dose-proportional exposure. Overall, 31 of 62 patients had stable disease and 1 patient (ovarian cancer) had a partial response per Rustin criteria. Voreloxin showed an acceptable safety profile with clinical activity in patients with relapsed/refractory solid tumors. The MTD was schedule-dependent. Voreloxin is currently in clinical studies of ovarian cancer and acute myeloid leukemia.
    Fait partie de: Clinical cancer research : an official journal of the American Association for Cancer Research, 01 April 2010, Vol.16(7), pp.2167-75
    Identifiant: 1078-0432 (ISSN); 20233886 Version (PMID); 10.1158/1078-0432.CCR-09-2236 (DOI)

    • Article
    Sélectionner

    Late-time Spectral Observations of Type IIP Supernovae

    Silverman, Jeffrey M, Pickett, Stephanie, Wheeler, J. Craig, Filippenko, Alexei V, Benvenuti, Piero
    Proceedings of the International Astronomical Union, 2015, Vol.11(A29B), pp.472-472 [Revue évaluée par les pairs]
    Cambridge University Press
    Disponible
    Plus…
    Titre: Late-time Spectral Observations of Type IIP Supernovae
    Auteur: Silverman, Jeffrey M; Pickett, Stephanie; Wheeler, J. Craig; Filippenko, Alexei V; Benvenuti, Piero
    Echelle: 2015
    Collection: 20161027
    Sujet: Contributed Papers; Supernovae: General; Techniques: Spectroscopic
    Description: We are analysing late-time (older than about 150 d past explosion) optical spectra of Type II-Plateau (IIP) supernovae (SNe), which are H-rich SNe that come from red supergiant (RSG) progenitors. The dataset includes nearly 100 spectra of about 40 objects, making this the largest sample of SN IIP nebular spectra ever investigated. Quantitative criteria from within the spectra themselves are employed to determine if an observation is truly nebular, and thus should be included in the study. We present the temporal evolution of the fluxes, shapes, and velocities of various emission lines (see, for example, Fig. 1). These measured values are also compared to photometric data in order to search for correlations that can allow us to gain insight into the diversity of RSG progenitors and learn more about the details of the explosion itself.
    Précédemment: 20162015100827
    Fait partie de: Proceedings of the International Astronomical Union, 2015, Vol.11(A29B), pp.472-472
    Classement: 201508
    Identifiant: 1743-9213 (ISSN); 1743-9221 (E-ISSN); 10.1017/S1743921316005895 (DOI)